Drugs / Phentermine-Topiramate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03374956 | Dec 2017 → May 2022 | obesity disorder | Mayo Clinic | Completed | Met primary |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01922934 | Jan 2014 → Aug 2016 | obesity disorder | Denver Health and Hospital Authority | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05812183 Background | Jul 2023 → Feb 2025 | — | University of California, Los Angeles | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-01-07 | VIVUS LLC | New Data Further Demonstrate Effectiveness of VIVUS Qsymia as a Weight Management Tool vivus.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | phentermine-topiramate | “Phentermine or phentermine-topiramate (Qsymia)” NCT01922934 ↗ |
| Known as | Qsymia | “Phentermine or phentermine-topiramate (Qsymia)” NCT01922934 ↗1“Phentermine-topiramate (Qsymia)” NCT05812183 ↗ |
| Route | Oral | “7.5/46 mg oral daily” NCT03374956 ↗ |